We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
How to use a quasi-experimental study to evaluate your digital health product.
Guidance on choosing evaluation study types and methods.
The MHRA has received reports describing a positive bias in HbA1c results delivered by the Trinity Biotech Premier Hb9210 HbA1c analyser, which has resulted in patients being incorrectly diagnosed as pre-diabetic or diabetic.
A government agency based in Singapore engaged Resaro’s assurance services to ensure that a LLM-based testimonial generation tool is unbiased with respect to gender and race and in-line with the agency’s requirements.
How to use a randomised controlled trial to evaluate your digital health product.
Things to consider when buying or using cosmetics.
How the MHRA makes decisions on whether a borderline product is a medical device and which risk class should apply.
How the MHRA makes decisions on what is a medicinal product (borderline products).
Do not include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).